February 18, 2025 02:44 PM EST

Novo looks to recoup $830M from hypertension drug partner, claiming fraud

Max Bayer

Pharma Reporter

A judge in Singapore ordered the freezing of KBP Biosciences’ assets while Novo Nordisk pursues $830 million in damages over claims that it was deceived …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo looks to recoup $830M from hypertension drug partner, claiming fraud

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Former FDA chief calls job cuts ‘haphazard, poorly thought-out’

NIH payment cuts are 'reasoned and rational,' government says

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

As part of turnaround, Solid Bio reports promising initial data for Duchenne gene therapy

Arcus touts early kidney cancer data as Gilead declines option

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

No­vo looks to re­coup $830M from hy­per­ten­sion drug part­ner, claim­ing fraud

Pharma Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novo looks to recoup $830M from hypertension drug partner, claiming fraud